Back to Search Results
Image Place holder

Valentina Tarasova, MD

★★★★★
★★★★★
4.9 (212 ratings)
Specialty: Endocrinology
Sub Specialty: Endocrinology, Diabetes & Metabolism
Program: Endocrine Oncology

Call 1-888-663-3488

Call 1-888-663-3488


Locations:
Overview

Cancer Focus: Adrenal Carcinoma, Adrenal Nodule/Mass, Neuroendocrine Tumor, Pituitary Macroadenoma, Pituitary Microadenoma, Pituitary Neoplasm, Thyroid Cancer, Thyroid Nodule/Mass

Dr. Tarasova is an Endocrinologist specializing in Endocrine Oncology at Moffitt Cancer Center. She completed an Internal Medicine Residency at Yale New Haven Hospital, Saint Raphael Campus, Yale School of Medicine in New Haven, CT and an Endocrinology, Diabetes and Metabolism Fellowship at the Creighton University in Omaha, NE. Most recently, Dr. Tarasova has completed an Interdisciplinary Medical Thyroid Cancer Fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. She also completed the Global Clinical Scholars Research Training (GCSRT) Program at Harvard Medical School in Boston, MA. Dr. Tarasova’s clinical interests include thyroid neoplasm, particularly diagnosis, monitoring and treatment of thyroid carcinoma (from low risk to advanced progressive forms of thyroid cancer). Her research interests include the role of molecular markers in diagnosing and determining the prognosis of thyroid neoplasm, risk stratification of patients with thyroid cancer and developing tools to estimate the prognosis and determine the management of patients with thyroid cancer.   


Education & Training

Board Certification:

  • Internal Medicine - Endocrinology, Diabetes & Metabolism

Fellowship:

  • Creighton University - Endocrinology, Diabetes, Metabolism
  • Memorial Sloan Kettering Cancer Center - Thyroid Cancer

Residency:

  • Yale New Haven Hospital, Yale School of Medicine - Internal Medicine

Medical School:

  • Kubansky State Medical University - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Hernandez-Prera J, Valderrabano P, Creed J, de la Iglesia JV, Slebos R, Centeno BA, Tarasova V, Hallanger-Johnson J, Veloski C, Otto KJ, Wenig BM, Yoder S, Lam C, Park DS, Anderson AR, Raghunand N, Berglund A, Caudell J, Gerke TA, Chung CH. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2021 Jan.31(1):36-49. Pubmedid: 32689909. Pmcid: PMC7864115.
  • Bayona A, Benavent P, Muriel A, Abuchaibe C, Sharpe SC, Tarasova V, McIver B, Valderrabano P. Outcomes of repeat fineneedle aspiration biopsy for AUS/FLUS thyroid nodules. Eur J Endocrinol. 2021 Aug.185(4):497-506. Pubmedid: 34313606.
  • Valderrabano P, Khazai L, Thompson ZJ, Sharpe SC, Tarasova VD, Otto KJ, Hallanger-Johnson JE, Wadsworth JT, Wenig BM, Chung CH, Centeno BA, McIver B. Cancer Risk Associated with Nuclear Atypia in Cytologically Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis. Thyroid. 2018 Feb.28(2):210-219. Pubmedid: 29160163. Pmcid: PMC7869885.
  • Tarasova VD, Tuttle RM. Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma. Clin Oncol (R Coll Radiol). 2017 May.29(5):290-297. Pubmedid: 28087101.
  • Tarasova VD, Tuttle RM. A Risk-adapted Approach to Follow-up in Differentiated Thyroid Cancer. Rambam Maimonides Med J. 2016 Jan.7(1). Pubmedid: 26886955. Pmcid: PMC4737510.
  • Shah KK, Tarasova V, Davidian M, Anderson RJ. Painful acute radiation thyroiditis induced by 131I treatment of Graves' disease. BMJ Case Rep. 2015 Jan.2015. Pubmedid: 25576511. Pmcid: PMC4289741.
  • Tarasova VD, Caballero JA, Turner P, Inzucchi SE. Speaking to Patients About Diabetes Risk: Is Terminology Important?. Clin Diabetes. 2014 Apr.32(2):90-95. Pubmedid: 26130869. Pmcid: PMC4485246.
  • Tarasova VD, Zena M, Rendell M. Artifactual hypoglycemia: an old term for a new classification. Diabetes Care. 2014.37(5):e85-e86. Pubmedid: 24757247.
  • Tarasova VD, Trepp-Carrasco AG, Thompson R, Recker RR, Chong WH, Collins MT, Armas LA. Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J Clin Endocrinol Metab. 2013 Nov.98(11):4267-4272. Pubmedid: 24014621. Pmcid: PMC5399525.

Patient Comments
Overall Satisfaction
4.9
★★★★★
★★★★★

212 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments